Alzheimer disease (AD) is the most common cause of dementia in the elderly, and is characterized by extracellular deposition of b-amyloid and intracellular accumulation of hyperphosphorylated tau protein in the brain. These pathologic findings are identified postmortem. Various visual deficits in AD have been reported and there have been conflicting reports, through imaging and pathology studies, regarding the presence of changes in the globe that mirror Alzheimer changes in the brain. Moreover, both macular degeneration and glaucoma have been variously characterized as having AD-related features. We examined one or both eyes from 19 autopsy cases, 17 of which had varying degrees of AD-related changes, and 2 of which were age-matched controls. Three cases had glaucoma and 4 had macular degeneration. Immunohistochemistry for tau, b-amyloid, TDP-43, ubiquitin, and a-synuclein showed no evidence of inclusions, deposits or other protein accumulation in any case, in any part of the globe. This finding suggests that regardless of the severity of changes seen in the brain in AD, there are no similar changes in the globe.
INTRODUCTION
Alzheimer disease (AD) is the most common cause of dementia in the elderly, and is characterized by neuronal loss in the cerebral cortex, extracellular deposition of b-amyloid, and intracellular accumulation of hyperphosphorylated tau protein in the brain. The final diagnosis is made based on autopsy brain findings. Various visual deficits in AD have been reported and there have been conflicting reports, through imaging and pathology studies, regarding the presence of changes in the lens and retina that mirror Alzheimer changes in the brain. This study aims to evaluate the presence of these changes in the eye for possible use in diagnosis and disease monitoring.
The ocular globe contains a rich supply of nerve tissue. The retina is composed of multiple layers of neurons and axons connected by synapses, including the optic nerve fiber layer, ganglion cell layer, inner and outer plexiform layers, inner and outer nuclear layers, and a layer of rods and cones. The retina also contains glial cells, such as Müller glia, which support the neurons. In addition, structures such as the cornea, iris, and ciliary body are well innervated by sensory or autonomic nerve fibers. This extensive supply of neurons, glia, and nerves make evaluating eye structures for AD-related changes an attractive area for exploration.
The notion that AD changes occur in the eye has been present for decades, with initial postmortem studies showing an association of AD with moderate reduction in retinal ganglion cells, thinning of the retinal nerve-fiber layer, and axonal degeneration of the optic nerve (1, 2) . More recent studies using optical coherence tomography have confirmed these findings, as well as shown functional defects in the retina (3) (4) (5) (6) (7) (8) and retinal vasculature changes (9) . In addition, patients with AD have an increased risk for age-related macular degeneration (10) .
Numerous transgenic mouse models of AD have reported retinal findings of hyperphosphorylated tau and b-amyloid (11) (12) (13) (14) (15) . Other studies on mouse models using spectrophotometric and fluorochrome plaque-labeling techniques have reported that the amyloid deposits in retina can precede cognitive decline (16) , and can be identified through noninvasive imaging modalities (16) (17) (18) .
Reports of deposits in humans have been varied. The first reports using light microscopy showed no neurofibrillary tangles or amyloid angiopathy in 4 (1) and 12 autopsy retinas from patients with AD (2). The latter study also confirmed these findings via evaluation of ultrastructural characteristics.
More recent reports have evaluated for the presence of deposits with immunohistochemistry, starting with evaluation by Loffler et al of amyloid precursor protein (APP), b-amyloid, and non-phosphorylated tau in the retina of older patients and patients with retinitis pigmentosa (RP) and age-related macular degeneration (ARMD, 19) . No age-related changes were identified in the staining pattern of tau. Retinal ganglion cells of older cases and the retinal pigment epithelium of eyes with RP and ARMD showed increased staining for APP.
Patchy staining of b-amyloid was also identified within the sub-retinal pigment epithelium of older subjects. Of note, in this study, none of the 40 total cases were from patients with known AD. Another study examined eyes from 19 cases (ages 49 to 87 years), of which 2 had clinical dementia, and found no phospho-tau or b-amyloid deposits in any of the cases (20) . This study also reported that older patients had increased frequency of ubiquitin and a-synuclein intracytoplasmic inclusions in the inner nuclear layer of the retina (20) . KoronyoHamaoui et al reported b-amyloid deposits in postmortem eyes by immunohistochemistry on cryosections, in 8 cases of definitive AD and 5 cases of suspected early stage AD. Plaques were not detected in 5 age-matched controls (17) . A study by Schön et al showed that the eyes of 6 AD patients were all negative for b-amyloid, and 5 of 6 had deposits of hyperphosphorylated tau (21) . A study by Ho et al revealed no evidence of phospho-tau or b-amyloid deposits in any part of the eyes of 11 cases of autopsy-confirmed AD (22) . Through a variety of techniques including immunohistochemistry and Western blot, 2 studies by the same group showed that ocular lenses from subjects with AD and Down syndrome contain deposits of b-amyloid (23, 24) . However, some have raised concerns regarding performing and validating these findings, with Michael et al identifying no material diagnostic for amyloid (25, 26) .
Many incongruous findings exist in the literature (Table 1) . Antibodies not used in the autopsy diagnosis of AD were used, such as APP, and non-standard techniques were used, including staining performed on cryosections. Small cohorts and cohorts without established diagnoses of AD were examined. Some did not concurrently examine the brain, making the assessment of comparable deposits impossible. In this study, we evaluate a sizeable cohort, examining both the eyes and brain of each case for AD-related changes and other pathological findings, using the standard techniques used for autopsy diagnosis of AD.
MATERIALS AND METHODS
We examined one (4 cases) or both eyes (13 cases) from 17 autopsy cases of AD and both eyes from 2 age-matched controls chosen from autopsy records from Massachusetts General Hospital. Demographic data as well as concurrent ophthalmological changes were recorded. The brain from each case was examined for pathological abnormalities, with sections taken from the superior and inferior frontal cortex, motor sensory strip, superior and inferior parietal cortex, temporal lobe, cingulate gyrus, calcarine cortex, hippocampus, basal ganglia, amygdala, thalamus, brainstem, and cerebellum. Immunohistochemistry for tau was performed on superior frontal cortex, superior and inferior parietal cortex, calcarine cortex, hippocampus, amygdala, and cingulate gyrus. Immunohistochemistry for b-amyloid was performed on these sections and basal ganglia, midbrain and cerebellum. The sections taken and immunohistochemistry performed were based on standard protocols established to determine the presence of AD-related changes in the brain, recorded by Thal stage, Braak and Braak tangle stage, and CERAD age-related plaque score (27) (28) (29) (30) (31) (32) . These staging systems are based on the stereotypical spatiotemporal progression of b-amyloid positive plaques and phospho-tau positive neurofibrillary tangles (NFTs) in AD. Thal stage is based on a progression of amyloid deposition in 5 stages: Stage 1 or isocortical; Stage 2, with additional allocortical deposits (entorhinal cortex, hippocampal formation, amygdala, insular, and cingulated cortices); Stage 3, with added involvement of subcortical nuclei including striatum, basal forebrain cholinergic nuclei, thalamus and hypothalamus, and white matter; Stage 4, distinguished by the involvement of brainstem structures, including red nucleus, substantia nigra, reticular formation of the medulla oblongata, superior and inferior colliculi; and Stage 5, with additional amyloid deposits in the pons (reticular formation, raphe nuclei, locus ceruleus) and the molecular layer of the cerebellum (27) . Braak tangle stage includes 6 stages of NFTs: the first NFTs appear in the transentorhinal region (stage I) and the entorhinal cortex, then in the CA1 region of the hippocampus (stage II). Next, NFTs appear in limbic structures such as the subiculum of the hippocampal formation (stage III) and the amygdala, thalamus, and claustrum (stage IV). NFTs subsequently extend to all isocortical areas (isocortical stage), with the associative areas being affected prior and more severely (stage V) than the primary sensory, motor, and visual areas (stage VI) (28) . CERAD age-related plaque score is based on the density of neuritic plaques (reported as sparse, moderate and severe) in the most severely affected region of isocortex (frontal, temporal, or parietal), and the patient's age at death (29) . All neuropathological and ophthalmological evaluations were performed at the same institution.
The eyes and brain were removed at autopsy, fixed in formalin, and sections taken were paraffin embedded. For each globe, 2 cross sections were processed to include representative structures, including lens, optic nerve and retina. 
RESULTS
The mean age of the cohort was 77 years with 52% male patients. Seventeen cases had varying degrees of AD-related changes (Table 2) . No known cases of familial AD were included in the series. The presence of AD-related changes, cerebral amyloid angiopathy, and other neuropathological and ophthalmic findings for each case are shown in Table 2 . Two age-matched controls were included (Cases 18, 19) . No definite inclusions were identified with immunohistochemistry for tau, b-amyloid, ubiquitin, TDP-43, or a-synuclein in any part 
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of the eye, including retina ( Fig. 2A, B) , lens, and optic nerve. Immunohistochemistry was performed in the standard fashion on brain sections for diagnosis of AD, which included stains for tau and b-amyloid (Fig. 2C, D) . Concurrent ophthalmological observations on H&E included cataracts (2 cases), agerelated macular degeneration (3 cases), open angle glaucoma (4 cases), and optic nerve atrophy (1 case) ( Table 2 ; Fig. 3A ).
No cerebral amyloid angiopathy was identified within the retinal vasculature of any case. No immunohistochemical staining for phospho-tau, b-amyloid, ubiquitin, TDP-43, or asynuclein was identified in these ophthalmic pathologies (Fig. 3B, C) .
DISCUSSION
AD is the most common cause of dementia in the elderly. A particular focus has been placed on early diagnosis to initiate treatment as early as possible. The eye is a particularly appealing site given it contains an abundant supply of nervous tissue. This includes retina, which holds multiple interconnected layers of neurons and transmits to the optic nerve, and well-innervated structures such as the cornea and the iris. The globe is directly connected to the brain and is accessed more easily than the brain for potential diagnostic tests. In addition to early diagnosis, ocular tests could possibly monitor AD progression or response to treatment.
In our study, immunohistochemistry for tau, b-amyloid, TDP-43, ubiquitin, and a-synuclein showed no evidence of inclusions, deposits or other protein accumulation in any case, in any part of the globe. Immunohistochemistry standardization is indispensable for reliable and reproducible results. We used identical protocols and positive controls for each globe and brain case. Each specimen, following removal at autopsy, was fully formalin fixed for a minimum of 2 weeks. Identical tissue processing was performed, including paraffin embedding and slide-drying time and temperature. The same antibodies, antibody dilution, antigen retrieval, incubation times, and automated platforms were used, to ensure consistent results. Tau deposition and b-amyloid plaques were present in the brain of these cases, and showed strongly positive immunostaining. These findings suggest that regardless of the severity of changes seen in the brain in AD, there are no similar changes in the globe. AD cannot be readily diagnosed or monitored via ophthalmological examination using methods with similar sensitivity to standard immunohistochemical techniques. These findings are in agreement with some studies and in disagreement with others (Table 1) . Multiple studies, including those by Hinton et al, Loffler et al, and Leger et al failed to identify any inclusions, with the latter 2 confirming their findings with immunohistochemistry (1, 19, 20) . Schön et al and Ho et al found similar findings with immunohistochemistry, with the exception of hyperphosphorylated but not fibrillar tau found in the retina from AD patients by Schön et al (21, 22) . Koronyo-Hamaoui et al identified amyloid plaques in early and confirmed AD through immunofluoresecent analysis of frozen material, which may be a more sensitive diagnostic test (17) . In addition, they examined retinal whole mounts, which includes more tissue than cross sectional evaluation used here.
Other methods for early diagnosis of AD via ocular biomarkers have been suggested, such as b-site APP-cleaving enzyme 1 (BACE1 [34] ) and retinal vascular changes. In APP/PS-1 transgenic mice, changes in BACE1 expression level occur earlier in the retina than in the brain and occur before behavioral deficits, but these observations may reflect transgene promoter effects (34) . Several groups have examined retinal blood vessels. Frost and colleagues compared brain amyloid plaque burden to multiple retinal vasculature parameters obtained through retinal photography and were able to predict healthy individuals with high plaque burden based on 2 of these parameters (venular branching asymmetry factor and arteriolar length-to-diameter ratio) (35) . Williams et al showed that subjects with lower venular fractal dimension and lower arteriolar tortuosity were more likely to have AD (9). The increased risk of ARMD in AD is discussed in the literature (10) , although the pathophysiology of this connection is not understood. It has been suggested that tau or b-amyloid deposits may play a role (10, 36) . Three cases in our group of patients had both AD and ARMD. None of these globes had phospho-tau or b-amyloid deposits in the eye, with specific focus on the retinal pigment epithelium, choriocapillaris, and drusen. In addition, reports have shown an increased incidence of primary open angle glaucoma among AD patients, and some patients with glaucoma have shown an increase in phospho-tau in specific parts of the retina (36) . In our 4 cases of concurrent AD and open angle glaucoma, no phospho-tau deposits within the retina were identified. This suggests that deposits of these proteins do not play a prominent role in the pathogenesis of ARMD and glaucoma in patients with AD. Finally, there have been mixed reports of b-amyloid deposits in the lenses from patients with cataracts and AD (23, 25) . The observations, made indirectly with an optical imaging approach, suggest amyloid deposits in the lens, but no amyloid deposits were observed in the lens of the patients examined in this series.
In conclusion, upon examination of both brain and eyes from AD subjects using the standard techniques used at Massachusetts General Hospital, no similar AD changes are found in the globe. This is in disagreement with some prior studies, and could be explained by differences in technique and sensitivity. In addition, no deposits were found in patients with both AD and other ophthalmic pathologies, indicating that deposits similar to those in the brain are not part of the pathophysiology of these diseases.
